Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Jie Zhang
Institutions:
Tianjin Medical University Cancer Institute and Hospital,
Tianjin Medical University
Observed institutions:
Tianjin Medical University Cancer Institute and Hospital,
Tianjin Medical University
ORCID:
0000-0003-3723-0056
Observed ORCID:
0000-0003-3723-0056
OpenAlex ID:
A5007157236
Real‐world data for the renal safety of abemaciclib combined with bisphosphonate in HR +/ HER2 − advanced breast cancer
2022
·
Chunfang Hao
, Xuedong Bai
, et al.
·
Thoracic Cancer
·
4
PDF
Recent advances in systemic treatment for HER2-negative breast cancer with brain metastases
2026
·
Chunfang Hao
, Jie Zhang
, et al.
·
Critical Reviews in Oncology/Hematology
·
3
Efficacy and safety of pyrotinib combined with trastuzumab emtansine (T-DM1) for patients with advanced HER2-positive breast cancer (BC): A single-arm phase II trial.
2024
·
Chunfang Hao
, Xiaowei Qi
, et al.
·
Journal of Clinical Oncology
·
2
Comparative effectiveness of CDK4/6 inhibitor plus endocrine therapy combinations in HR-positive, HER2-negative metastatic breast cancer: the inspiration 01 study
2026
·
Yan Jia
, Jie Zhang
, et al.
·
Frontiers in Pharmacology
PDF
Show more works
View as search
Works count:
4
Citation count:
9
H-index:
2
I10-index:
Year
Topic
Type